查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2011265

感染疾病診斷市場：2026-2032年全球市場預測（依產品類型、檢體類型、檢測類型、病原體類型、疾病類型和最終用戶分類）

Infectious Disease Diagnostic Market by Product, Sample Type, Testing Type, Pathogen Type, Disease Type, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，感染疾病診斷市場價值將達到 270.6 億美元，到 2026 年將成長至 294.1 億美元，到 2032 年將達到 492.8 億美元，複合年成長率為 8.93%。

主要市場統計數據
基準年 2025 270.6億美元
預計年份：2026年 294.1億美元
預測年份 2032 492.8億美元
複合年成長率 (%) 8.93%

揭示塑造現代感染疾病檢測的關鍵促進因素和技術創新。

感染疾病診斷領域正處於關鍵的轉折點，儀器和軟體整合的技術突破與日益成長的臨床需求（即更快、更準確的檢測結果）交匯融合。無論是在檢查室還是臨床環境中，快速檢測病原體並保持嚴格的靈敏度和特異性標準都面臨越來越大的壓力。在此背景下，從醫院網路到學術研究機構，醫療保健領域的各相關人員都必須調整其營運結構，以充分利用新一代工具和工作流程。

自動化、數據分析和分散式檢查模型如何改變病原體檢測和臨床決策流程。

感染疾病診斷領域正因自動化、高通量檢測能力和數據分析的整合而煥然一新，檢查室能夠以前所未有的規模處理檢體。包括質譜和次世代定序在內的尖端檢測方法，與免疫檢測和PCR技術相輔相成，使得在極短的周轉時間內檢測多種病原體（如細菌、病毒、真菌和寄生蟲）成為可能。

在不斷變化的關稅制度下維持診斷測試業務：應對新的貿易壁壘並進行策略性採購協調。

2025年全年實施的關稅政策為傳染病檢查中使用的進口試劑、設備和關鍵零件帶來了新的成本考量。許多診斷檢查室面臨著從受影響地區採購的抗原檢測試劑盒和免疫檢測設備成本上漲的問題，採購團隊正在尋找國內替代供應商，並調整檢測量以緩解預算限制。

整合產品、檢體、測試、病原體、疾病和最終用戶觀點，揭示個人化診斷路徑。

有效的市場區隔技術揭示了產品類型之間的細微差別，突顯了儀器、試劑/試劑盒和軟體解決方案的不同應用模式。在儀器領域，免疫檢測分析儀在常規篩檢方面保持強勁的臨床需求，而質譜儀和微陣列則滿足了專業研究應用的需求。 PCR 系統在中心檢查室和照護現場(POC) 環境中的應用範圍持續擴大。試劑和試劑盒的應用也十分廣泛：抗原檢測方法在快速檢測中表現出色，ELISA 和免疫檢測盒支持高通量工作流程，而 PCR 試劑盒則在分子診斷中展現出無與倫比的靈敏度。

分析影響全球診斷技術創新和部署模式的區域醫療基礎設施和政策因素。

在美洲，成熟的醫療基礎設施和健全的報銷體系持續推動先進診斷平台的應用。北美地區的參考檢查室和學術研究中心網路主導新型檢測方法的檢驗，而在拉丁美洲，不斷擴大的公共衛生舉措正在推動對經濟高效的快速檢測方法的需求成長。經濟多元化和政府對分子診斷的投資正在增強實施大規模篩檢計畫的能力。

探索策略合作夥伴關係和平台整合，以加速檢測方法開發並推動可擴展的診斷解決方案。

一群成熟的儀器製造商和新興的試劑研發公司正在攜手合作，以期將研究檢測方法快速應用於臨床。微陣列供應商與軟體公司之間的合作，實現了無縫的數據分析流程；而試劑盒製造商與參考實驗室之間的合資企業，則確保了在各種臨床條件下進行嚴格的性能檢驗。

建立強大的製造系統、數據驅動的洞察力和協作網路，以加快診斷敏捷性和市場回應速度。

經營團隊應優先考慮製造地多元化，以降低供應鏈脆弱性，並減少貿易政策波動帶來的風險。透過採用靈活的關鍵試劑和設備生產模式，企業可以根據區域疫情爆發迅速擴大生產規模。此外，投資模組化、軟體主導的平台有助於無縫整合新的檢測方法，並縮短新病原體標靶的上市時間。

全面的資料收集、專家訪談和詳細的分類系統確保了客觀、實用的市場分析。

本分析整合了從對診斷檢測實驗室高級官員、檢測套組製造商、軟體開發商和醫療政策制定者的詳細訪談中獲得的第一手資訊。第二手研究則利用同行評審期刊、監管文件和公共衛生機構報告，檢驗了技術採納趨勢和區域部署模式。我們應用了一套專有框架來繪製產品和疾病分類圖，確保在儀器、試劑、檢體類型和最終用戶群體之間採用一致的分類系統。

加強適應性技術和協作策略在塑造感染疾病檢測未來中的作用。

隨著全球醫療衛生體系持續面臨新興感染疾病的威脅，快速檢測和鑑定病原體的能力仍然是有效應對策略的基礎。檢測方法的技術進步，加上強大的軟體整合和分散式檢查能力，正在重新定義診斷工作流程，並實現主動式病患管理。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：感染疾病診斷市場：依產品分類

  • 裝置
    • 免疫檢測裝置
    • 質譜儀
    • 微陣列
    • PCR系統
  • 試劑和試劑盒
    • 抗原檢測試劑盒
    • ELISA試劑盒
    • 免疫檢測盒
    • PCR試劑盒
  • 軟體

第9章：依檢體類型分類的感染疾病診斷市場

  • 血
  • 航班
  • 拭子
    • 鼻腔
    • 直腸
    • 咽
  • 尿

第10章：依檢測類型分類的感染疾病診斷市場

  • 臨床試驗
  • PoC測試

第11章：以病原體分類的感染疾病診斷市場

  • 細菌
  • 真菌
  • 寄生蟲
  • 病毒性的
    • 肝炎
    • HIV
    • 流感

第12章：感染疾病診斷市場：依疾病類型分類

  • 細菌性行為感染
    • 腦膜炎
    • 肺炎
    • 結核
  • 黴菌感染疾病
    • 麴菌症
    • 念珠菌症
    • 隱球菌病
  • 寄生蟲感染疾病
    • 利什曼原蟲症
    • 瘧疾
    • 血吸蟲病
  • 媒介性行為感染感染
    • 登革熱
    • 萊姆病
    • 茲卡病毒
  • 性行為感染
    • 肝炎（甲型、乙型、丙型）
    • 乙型和丙型肝炎
    • 愛滋病毒/愛滋病
    • 流感

第13章：感染疾病診斷市場：依最終用戶分類

  • 學術和研究機構
  • 診斷檢查室
  • 醫院和診所

第14章：感染疾病診斷市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：感染疾病診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：感染疾病診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國感染疾病診斷市場

第18章：中國感染疾病診斷市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Adaptive Biotechnologies Corporation
  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • bioMerieux SA
  • Boston Scientific Corporation
  • Bruker Corporation
  • Cardinal Health Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • GE HealthCare Technologies Inc.
  • Grifols, SA
  • Hologic Inc.
  • Illumina, Inc.
  • Johnson & Johnson Services Inc.
  • Konica Minolta, Inc.
  • Koninklijke Philips NV
  • MedMira Inc.
  • Medtronic PLC
  • Merck KGaA
  • Olympus Corporation
  • Perkin Elmer, Inc.
  • Pfizer Inc.
  • Qiagen NV
  • Quest Diagnostics Incorporated
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific, Inc.
  • Trivitron Healthcare
Product Code: MRR-4316E4E89510

The Infectious Disease Diagnostic Market was valued at USD 27.06 billion in 2025 and is projected to grow to USD 29.41 billion in 2026, with a CAGR of 8.93%, reaching USD 49.28 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 27.06 billion
Estimated Year [2026] USD 29.41 billion
Forecast Year [2032] USD 49.28 billion
CAGR (%) 8.93%

Unveiling Critical Drivers and Technological Innovations Shaping Modern Infectious Disease Detection

The infectious disease diagnostics arena stands at a pivotal juncture, where technological breakthroughs in instrumentation and software integration converge with rising clinical demands for faster, more precise results. Laboratories and point-of-care settings alike are under increasing pressure to deliver rapid pathogen detection while maintaining rigorous standards of sensitivity and specificity. In this context, stakeholders across the healthcare spectrum-ranging from hospital networks to academic research institutes-must adapt their operational frameworks to harness next-generation tools and workflows.

Against this backdrop, this executive summary synthesizes critical drivers shaping the diagnostics market, highlights regulatory and policy trends influencing global supply chains, and presents actionable frameworks for segmentation, regional analysis, and competitive positioning. By exploring transformative shifts, tariff impacts, and nuanced market segmentation, readers will gain a holistic perspective on how to navigate the complexities of diagnostic innovation, optimize resource allocation, and deliver improved patient outcomes in an increasingly interconnected healthcare ecosystem.

How Automation, Data Analytics, and Decentralized Testing Models Are Revolutionizing Pathogen Detection and Clinical Decision Pathways

The infectious disease diagnostic sector is being reshaped by a convergence of automation, high-throughput capabilities, and data analytics that enable laboratories to process samples at unprecedented scale. Cutting-edge assays compatible with mass spectrometry and next-generation sequencing are complementing immunoassay and PCR technologies, allowing for multiplexed detection of bacterial, viral, fungal, and parasitic pathogens with remarkable turnaround times.

Meanwhile, the integration of cloud-enabled software platforms has streamlined data aggregation from instruments such as immunoassay analyzers and microarrays, supporting real-time surveillance and predictive modeling of outbreak patterns. This shift toward decentralized testing is further bolstered by advanced portable PCR systems and antigen detection kits, extending diagnostic reach beyond centralized labs into point-of-care settings. Consequently, clinical decision-making pathways are evolving to incorporate telehealth consultations informed by rapid test results, signaling a fundamental transformation in how infectious diseases are identified, monitored, and managed on a global scale.

Navigating New Trade Barriers and Strategic Sourcing Adjustments to Sustain Diagnostic Testing Operations Under Evolving Tariff Regimes

Tariff policies implemented throughout 2025 have introduced new cost considerations for imported reagents, instruments, and key components used in infectious disease testing. Many diagnostic laboratories have encountered increased expenses for antigen detection kits and immunoassay analyzers sourced from affected regions, prompting procurement teams to explore alternative domestic suppliers or adjust testing volumes to mitigate budgetary constraints.

In parallel, reagent and kit manufacturers have responded by diversifying regional manufacturing footprints, establishing production lines for ELISA, immunoassay, and PCR kits in tariff-exempt jurisdictions. Software developers for laboratory information management systems have also recalibrated pricing models to accommodate higher import costs for hardware integrations. Collectively, these measures have fostered a more resilient supply chain, though stakeholders must remain vigilant to potential delays and regulatory changes that could further influence global trade dynamics.

Integrating Product, Sample, Testing, Pathogen, Disease, and End-User Perspectives to Illuminate Tailored Diagnostic Pathways

An effective segmentation approach illuminates the nuanced drivers across product categories, revealing distinct adoption patterns in instruments, reagents and kits, and software solutions. Within instruments, immunoassay analyzers maintain strong clinical demand for routine screenings, while mass spectrometers and microarrays cater to specialized research applications. PCR systems continue to expand their footprint in both centralized laboratories and point-of-care settings. Reagents and kits exhibit diverse usage; antigen detection formats excel in rapid testing scenarios, ELISA and immunoassay kits underpin high-throughput workflows, and PCR kits deliver unmatched sensitivity for molecular diagnostics.

Sample type differentiation underscores the importance of specimen matrix compatibility, with blood derivatives such as plasma, serum, and whole blood dominating hospital-based testing and stool and urine assays facilitating gastrointestinal and urinary pathogen detection. Swab collections, spanning nasal, rectal, and throat formats, are pivotal for respiratory screening programs. Diagnostic methodologies fall broadly into laboratory testing and point-of-care modalities, each aligned with specific clinical contexts and throughput requirements. Pathogen focus spans bacterial, fungal, parasitic, and viral targets; within the viral cohort, hepatitis subtypes, HIV, and influenza command critical surveillance priority. Disease classifications span meningitis and pneumonia to vector-borne infections such as dengue and Zika, informing tailored assay development. Finally, end-user environments ranging from academic institutes to diagnostic laboratories and hospitals guide commercialization strategies and service level agreements for comprehensive diagnostic platforms.

Examining Regional Healthcare Infrastructures and Policy Drivers That Shape Diagnostic Innovation and Adoption Patterns Globally

In the Americas region, mature healthcare infrastructures and robust reimbursement frameworks continue to drive adoption of advanced diagnostic platforms. North America's network of reference laboratories and academic research centers spearheads validation of novel assays, while Latin American markets exhibit growing demand for cost-effective rapid tests amid expanding public health initiatives. Economic diversification and government investments in molecular diagnostics have bolstered capacity for large-scale screening programs.

Europe, Middle East, and Africa present a mosaic of requirements, from stringent regulatory compliance in Western Europe to emerging surveillance needs in the Middle East and resource-constrained settings across Africa. Collaborative efforts among public health agencies have accelerated deployment of point-of-care antigen tests and portable PCR systems during outbreak responses, redefining standard practices for decentralized testing.

Asia-Pacific markets showcase dynamic growth fueled by rising awareness of infectious disease preparedness and expanding digital health ecosystems. Government initiatives in countries such as China and India are catalyzing local manufacturing capabilities for reagents and instruments, while Southeast Asian nations integrate multiplexed assays into national screening programs. Across all regions, the convergence of technology, policy, and infrastructure investments is shaping a more agile and responsive diagnostic landscape.

Exploring Strategic Alliances and Platform Integrations Driving Faster Assay Development and Scalable Diagnostic Solutions

A cohort of established instrument manufacturers and emerging reagent developers are forging collaborative alliances to accelerate the translation of research-grade assays into clinical practice. Partnerships between microarray providers and software firms have enabled seamless data interpretation pipelines, while joint ventures between kit manufacturers and reference laboratories ensure rigorous performance validation under diverse clinical conditions.

Key diagnostic companies are investing in modular instrument architectures that support rapid assay deployment, leveraging scalable reagent supply chains to meet fluctuating demand during epidemic surges. Software integrators are enhancing interoperability with electronic health record systems to deliver actionable insights directly to clinicians. Collectively, these strategic initiatives underscore a shared commitment to driving continuous innovation, optimizing operational efficiencies, and strengthening the global diagnostics ecosystem through synergistic partnerships.

Building Resilient Manufacturing, Data-Driven Insights, and Collaborative Networks to Accelerate Diagnostic Agility and Market Response

Executives should prioritize the diversification of manufacturing footprints to mitigate supply chain vulnerabilities and reduce exposure to trade policy fluctuations. By adopting flexible production models for key reagents and instruments, organizations can rapidly scale output in response to local outbreak scenarios. Moreover, investing in modular, software-driven platforms will facilitate the seamless integration of new assay chemistries, shortening time to market for emerging pathogen targets.

Leaders must also foster cross-sector collaborations that bridge academic research, clinical laboratories, and public health agencies, creating feedback loops for continuous assay refinement. Embracing data-driven decision-making frameworks-leveraging predictive analytics from real-world testing data-will empower stakeholders to anticipate shifts in pathogen prevalence and deploy targeted diagnostic interventions. Finally, building comprehensive education programs for end-users can drive proficiency in advanced testing methodologies, ensuring optimal utilization of instruments and reagents across diverse care settings.

Detailing Rigorous Data Gathering, Expert Interviews, and Taxonomy Frameworks That Ensure Objective and Actionable Market Analysis

Our analysis synthesizes primary insights from in-depth interviews with senior executives at diagnostic laboratories, kit manufacturers, software developers, and healthcare policymakers. Secondary research leveraged peer-reviewed journals, regulatory filings, and public health agency reports to validate technology adoption trends and regional deployment patterns. Proprietary frameworks were applied to map product and disease classifications, ensuring a consistent taxonomy across instruments, reagents, sample types, and end-user segments.

Quantitative data was cross-referenced with historical trade and policy databases to assess tariff impacts, while real-world usage statistics were examined to refine segmentation insights. Scenario planning exercises facilitated the evaluation of strategic sourcing options and partnership models. All findings were peer reviewed by subject matter experts to ensure accuracy, relevance, and practical applicability for decision-makers seeking strategic guidance in the dynamic infectious disease diagnostics market.

Reinforcing the Role of Adaptive Technologies and Collaborative Strategies in Shaping the Future of Infectious Disease Detection

As the global healthcare ecosystem continues to confront emerging infectious threats, the ability to rapidly detect and characterize pathogens remains the cornerstone of effective response strategies. Technological advancements in assay modalities, combined with robust software integration and decentralized testing capabilities, are redefining diagnostic workflows and enabling proactive patient management.

By embracing diversified manufacturing, leveraging real-world data analytics, and cultivating strategic partnerships, stakeholders can navigate regulatory and trade complexities while delivering high-impact diagnostic solutions. Ultimately, the organizations that align operational agility with a deep understanding of regional and segment-specific dynamics will secure leadership positions and contribute meaningfully to improved global health outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Infectious Disease Diagnostic Market, by Product

  • 8.1. Instruments
    • 8.1.1. Immunoassay Analyzers
    • 8.1.2. Mass Spectrometers
    • 8.1.3. Microarrays
    • 8.1.4. PCR Systems
  • 8.2. Reagents & Kits
    • 8.2.1. Antigen Detection Kits
    • 8.2.2. ELISA Kits
    • 8.2.3. Immunoassay Kits
    • 8.2.4. PCR Kits
  • 8.3. Software

9. Infectious Disease Diagnostic Market, by Sample Type

  • 9.1. Blood
  • 9.2. Stool
  • 9.3. Swab
    • 9.3.1. Nasal
    • 9.3.2. Rectal
    • 9.3.3. Throat
  • 9.4. Urine

10. Infectious Disease Diagnostic Market, by Testing Type

  • 10.1. Laboratory Testing
  • 10.2. PoC Testing

11. Infectious Disease Diagnostic Market, by Pathogen Type

  • 11.1. Bacterial
  • 11.2. Fungal
  • 11.3. Parasitic
  • 11.4. Viral
    • 11.4.1. Hepatitis
    • 11.4.2. HIV
    • 11.4.3. Influenza

12. Infectious Disease Diagnostic Market, by Disease Type

  • 12.1. Bacterial Infectious Diseases
    • 12.1.1. Meningitis
    • 12.1.2. Pneumonia
    • 12.1.3. Tuberculosis
  • 12.2. Fungal Infections
    • 12.2.1. Aspergillosis
    • 12.2.2. Candidiasis
    • 12.2.3. Cryptococcosis
  • 12.3. Parasitic Infections
    • 12.3.1. Leishmaniasis
    • 12.3.2. Malaria
    • 12.3.3. Schistosomiasis
  • 12.4. Vector-borne Infections
    • 12.4.1. Dengue Fever
    • 12.4.2. Lyme Disease
    • 12.4.3. Zika Virus
  • 12.5. Viral Infectious Diseases
    • 12.5.1. Hepatitis (A, B, C)
    • 12.5.2. Hepatitis B & C
    • 12.5.3. HIV/AIDS
    • 12.5.4. Influenza

13. Infectious Disease Diagnostic Market, by End-User

  • 13.1. Academic & Research Institutes
  • 13.2. Diagnostic Laboratories
  • 13.3. Hospitals & Clinics

14. Infectious Disease Diagnostic Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Infectious Disease Diagnostic Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Infectious Disease Diagnostic Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Infectious Disease Diagnostic Market

18. China Infectious Disease Diagnostic Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. Adaptive Biotechnologies Corporation
  • 19.7. Agilent Technologies, Inc.
  • 19.8. Becton, Dickinson and Company
  • 19.9. Bio-Rad Laboratories, Inc.
  • 19.10. Bio-Techne Corporation
  • 19.11. bioMerieux SA
  • 19.12. Boston Scientific Corporation
  • 19.13. Bruker Corporation
  • 19.14. Cardinal Health Inc.
  • 19.15. Danaher Corporation
  • 19.16. F. Hoffmann-La Roche Ltd.
  • 19.17. GE HealthCare Technologies Inc.
  • 19.18. Grifols, S.A.
  • 19.19. Hologic Inc.
  • 19.20. Illumina, Inc.
  • 19.21. Johnson & Johnson Services Inc.
  • 19.22. Konica Minolta, Inc.
  • 19.23. Koninklijke Philips N.V.
  • 19.24. MedMira Inc.
  • 19.25. Medtronic PLC
  • 19.26. Merck KGaA
  • 19.27. Olympus Corporation
  • 19.28. Perkin Elmer, Inc.
  • 19.29. Pfizer Inc.
  • 19.30. Qiagen N.V.
  • 19.31. Quest Diagnostics Incorporated
  • 19.32. Siemens Healthineers AG
  • 19.33. Sysmex Corporation
  • 19.34. Thermo Fisher Scientific, Inc.
  • 19.35. Trivitron Healthcare

LIST OF FIGURES

  • FIGURE 1. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY MASS SPECTROMETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY MASS SPECTROMETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY MASS SPECTROMETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY MICROARRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY MICROARRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY MICROARRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PCR SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PCR SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PCR SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY ANTIGEN DETECTION KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY ANTIGEN DETECTION KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY ANTIGEN DETECTION KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY ELISA KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY ELISA KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY ELISA KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY IMMUNOASSAY KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY IMMUNOASSAY KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY IMMUNOASSAY KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PCR KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PCR KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PCR KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY STOOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY STOOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY STOOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY NASAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY NASAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY NASAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY RECTAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY RECTAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY RECTAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY THROAT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY THROAT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY THROAT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY LABORATORY TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY LABORATORY TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY LABORATORY TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY POC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY POC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY POC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY HEPATITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY HEPATITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY HIV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY HIV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY HIV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INFLUENZA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY MENINGITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY MENINGITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY MENINGITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PNEUMONIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PNEUMONIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PNEUMONIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TUBERCULOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TUBERCULOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TUBERCULOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY ASPERGILLOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY ASPERGILLOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY ASPERGILLOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY CANDIDIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY CANDIDIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY CANDIDIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY CRYPTOCOCCOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY CRYPTOCOCCOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY CRYPTOCOCCOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY LEISHMANIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY LEISHMANIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY LEISHMANIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY MALARIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY MALARIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY MALARIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SCHISTOSOMIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SCHISTOSOMIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SCHISTOSOMIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DENGUE FEVER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DENGUE FEVER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DENGUE FEVER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY LYME DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY LYME DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY LYME DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY ZIKA VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY ZIKA VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY ZIKA VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY HEPATITIS (A, B, C), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY HEPATITIS (A, B, C), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY HEPATITIS (A, B, C), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY HEPATITIS B & C, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY HEPATITIS B & C, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY HEPATITIS B & C, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY HIV/AIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY HIV/AIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY HIV/AIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INFLUENZA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 173. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 174. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 175. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
  • TABLE 177. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 180. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 182. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 183. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 184. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 185. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 186. AMERICAS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 196. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 198. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 200. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 202. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 212. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 214. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 216. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 218. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 252. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 254. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 260. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 262. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 264. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 266. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 267. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 268. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 269. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 270. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 271. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
  • TABLE 273. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 276. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 278. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 279. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 280. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 281. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 282. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 294. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 295. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 296. ASIA-PACIFIC INFECTIOUS DIS